Overview
Corporate Profile
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest News
View All
Nov 23, 2022
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
Read More
Nov 14, 2022
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
Read More
Nov 10, 2022
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
Read More
Nov 07, 2022
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
Read More
Nov 07, 2022
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
Read More
Nov 03, 2022
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
Read More
Oct 10, 2022
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
Read More
Sep 29, 2022
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
Read More
Sep 28, 2022
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
Read More
Sep 28, 2022
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
Read More
Sep 19, 2022
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
Read More
Sep 12, 2022
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
Read More
Aug 15, 2022
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
Read More
Aug 10, 2022
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Read More
Aug 08, 2022
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
Read More
Aug 01, 2022
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Read More
Jun 13, 2022
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
Read More
Jun 10, 2022
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
Read More
Upcoming Events
Dec 1, 2022 at 2:15 PM EST
Recent Events
Corporate Fact Sheet
Corporate Presentation
In the News
September 5, 2022
Source
The Wall Street Transcript
August 16, 2022
Source
Cell & Gene Therapy Insights
December 1, 2021
Source
Life Science Leader
December 1, 2021
Source
Life Science Leader
October 21, 2021
Source
Blood
July 20, 2021
Source
ASH Clinical News
July 16, 2021
Source
GeneTherapyLive
June 23, 2021
Source
Cell & Gene
June 22, 2021
Source
GeneTherapyLive
March 26, 2021
Source
Pharmacy Times
Investor & Media Contact
Heather DiVecchia
Director, Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com